Product image of Memantine Macleods (Memantine Hydrochloride) supplied by GNH India

Memantine Macleods

Active Ingredient:
Memantine Hydrochloride
Origin:
EU

Memantine Macleods (Memantine Hydrochloride)

Memantine Hydrochloride, the active ingredient in Memantine Macleods, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults. By modulating glutamatergic activity, it helps reduce neuronal excitotoxicity associated with disease progression.

GNH India supplies Memantine Macleods as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide.

Manufacturer / TM Owner

Macleods Pharma Uk Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Memantine acts on the glutamatergic pathway and is used in the management of Alzheimer’s disease.
  • Alzheimer’s disease (moderate to severe): improves cognition and functional abilities in patients with advanced disease.
  • Alzheimer’s disease (mild to moderate) as adjunct therapy: may enhance benefits when combined with cholinesterase inhibitors.
  • Behavioral disturbances in Alzheimer’s disease: can help reduce agitation and aggression in some patients.

How It Works

  • Memantine Hydrochloride is a non‑competitive antagonist of the NMDA (N‑methyl‑D‑aspartate) receptor. It binds to the receptor-associated ion channel at a site distinct from the glutamate binding site, reducing excessive calcium influx and thereby limiting excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Side Effects

Memantine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

  • Dizziness: sensation of light‑headedness or unsteadiness.
  • Headache: mild to moderate intensity.
  • Constipation: reduced bowel movements.
  • Confusion: transient mental clouding.
  • Fatigue: feeling unusually tired.
  • Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

  • Seizures: occurrence of convulsive episodes.
  • Severe allergic reactions: rash, swelling, or anaphylaxis.
  • Stevens‑Johnson syndrome: serious skin disorder.
  • Hepatic dysfunction: abnormal liver enzymes.
  • Cardiac arrhythmia: irregular heart rhythm.
  • Psychosis: new or worsening hallucinations or delusions.

Precautions & Warnings

  • Memantine should be used with caution in specific clinical situations.
  • Renal impairment: dose adjustment may be required.
  • History of seizures: monitor for increased seizure activity.
  • Cardiovascular disease: use cautiously due to potential blood pressure effects.
  • Concurrent NMDA antagonists: avoid combined use to prevent additive CNS depression.
  • Pregnancy and lactation: safety unknown; avoid unless clearly needed.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Memantine may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

  • Amantadine: additive NMDA antagonism may increase CNS effects.
  • Ketamine: combined use can lead to excessive sedation or respiratory depression.
  • Strong CYP450 inhibitors (e.g., ketoconazole): may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Anticholinesterase inhibitors: may diminish therapeutic benefit.
  • Diuretics: can potentiate hypotensive effects.
  • Alcohol: may enhance dizziness and sedation.

Frequently Asked Questions

Memantine Macleods contains memantine hydrochloride, which is prescribed to treat the cognitive symptoms of moderate to severe Alzheimer’s disease. It works by modulating glutamate activity in the brain, helping to preserve neuronal function and improve daily functioning in affected patients.

Memantine is a non‑competitive antagonist of the NMDA receptor. By binding to the receptor’s ion channel, it blocks excessive calcium influx caused by overstimulation with glutamate, thereby reducing excitotoxic neuronal damage that contributes to cognitive decline in Alzheimer’s disease.

The dosage of memantine is individualized by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. The prescriber determines the appropriate starting dose and any titration schedule required for safe and effective treatment.

The safety of memantine in pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas many other Alzheimer’s agents are cholinesterase inhibitors. Memantine is typically used in moderate to severe disease or as add‑on therapy, offering a different mechanism that targets excitotoxicity rather than acetylcholine breakdown.

Memantine tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Memantine Macleods is taken orally, usually once or twice daily as directed by the prescriber. The tablets should be swallowed whole with water and can be taken with or without food, following the dosing schedule set by the healthcare professional.

Serious risks include the potential for seizures, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, hepatic dysfunction, cardiac arrhythmias, and new or worsening psychosis. Patients should be monitored closely for any of these events, especially during treatment initiation.

Memantine is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists, as these conditions may increase the risk of adverse effects.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Memantine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT